Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to OFEV 100mg Capsules:
OFEV 100mg Capsules contain nintedanib, a medication classified as a tyrosine kinase inhibitor. It is primarily prescribed for the management of certain lung disorders, including idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Mechanism of Action of OFEV 100mg Capsules:
Nintedanib operates by inhibiting various receptor tyrosine kinases, such as fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR). By targeting these signaling pathways, it effectively retards the progression of fibrosis and diminishes inflammation within the lungs.
Uses of OFEV 100mg Capsules:
Idiopathic Pulmonary Fibrosis (IPF): OFEV 100mg Capsules are indicated for the treatment of IPF, a chronic lung ailment characterized by the accumulation of scar tissue in the lungs, leading to impaired lung function and respiratory difficulties.
Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Additionally, OFEV 100mg Capsules are utilized in the management of SSc-ILD, a lung disorder linked with systemic sclerosis, a connective tissue disorder. SSc-ILD induces lung fibrosis and can result in substantial impairment of lung function.
Benefits of OFEV 100mg Capsules:
Slows Disease Progression: Nintedanib has demonstrated significant efficacy in decelerating the decline of lung function in patients with IPF and SSc-ILD. It mitigates the rate of lung function deterioration, thereby enhancing quality of life and extending survival.
Reduces Acute Exacerbations: OFEV 100mg Capsules have been observed to diminish the frequency and severity of acute exacerbations, sudden exacerbations of symptoms, in IPF patients, which could potentially be life-threatening.
Improves Exercise Capacity: Clinical studies have indicated that Nintedanib can enhance exercise capacity in individuals with IPF, enabling them to engage in daily activities with greater ease.